Join the Hive

The Hive is a hub of innovation. It’s a group of leading edge biotech and pharmaceutical startups that are specially chosen, because of their impressive work in early stage drug discovery & development, to further power their efforts with complimentary access to Elsevier’s suite of R&D solutions.

Committed to promoting collaboration and inspiration across the Pharma & Life Sciences industry, The Hive is an opportunity for participating companies to accelerate their research and for others to learn from their experiences.

We are now accepting applications for our next cohort of participants.

Apply now

The Hive

Benefits for the participants


Learn more about Reset Therapeutics, a 2016 participant, and their experience in the program

Hear from our 2016 Hive participants

"Access to Elsevier R&D Solutions’ suite of programs allows us to move our project forward. The Hive also gives handson training of technologies that will help us make better informed decisions on lead compound selections, and will increase our productivity by reducing the time we spend searching for relevant and trustworthy data for our research." Claudia Bøen, CEO, Arctic Pharma
"In order to give ourselves the best leg up against our competitors and to give ourselves the best level of equivalence with the people who are going to be important to help us partner and go forward as a company in terms of laterstage clinical trial, we have to know what everybody else knows. The only way to do that is to have access to a good suite of tools like the Elsevier products in order to do that." Ross Bersot, CEO, Reset Therapeutics
"A big R&D challenge for a small company developing a platform technology that can be broadly applied across multiple disease areas is the ability to rapidly get up to speed on different disease areas and other technical areas critical toward improving the technology. This includes understanding the science and biology as well as the IP, clinical, and commercial landscapes. But that’s what is great about being a part of the The Hive. Hive participation has been an amazing resource in support of our effort to address this challenge." Tom Wickham, Vice President Research and Development at Rubius Therapeutics
"The fact that we have rapid access to Elsevier journals and can use Reaxys to look for reaction conditions, if we have an idea in our 10 o’clock meeting, we may have the chemistry working by that same afternoon." Bruce Clapham, Director of Medicinal Chemistry, Reset Therapeutics

Eligibility

Companies that are the best fit for the program meet the following four criteria:

  • Are not currently an Elsevier customer (or subsidiary of one)
  • Have at least 10 researchers focused on early stage research
  • Are pre-revenue
  • Are not looking to be acquired in the next 18 months

Not eligible? Follow The Hive instead:

How to apply

  1. Click here to complete the application by August 31
  2. Once the application is complete, you’ll receive a link to complete the Solution Finder tool which will tell us which solutions are most appropriate for your teams
  3. Applicants progressing to the interview round will be notified by September 15
  4. All applicants will be notified of their status by November 1

Questions, comments or inquiries about The Hive?
Send us a message.

Learn More About Elsevier R&D Solutions for Early Stage Drug Discovery and Development:

Reaxys

Improve R&D productivity with a chemistry research solution that delivers experimental facts on chemical structures, properties, reactions and procedures.

Learn more about Reaxys

Reaxys Medicinal Chemistry

Empower hit identification and lead optimization with normalized compound–target affinity data and comprehensive pharmacokinetic, efficacy, toxicity, safety and metabolic profiles.
Learn more about Reaxys Medicinal Chemistry

Embase

Increase the discovery of biomedical evidence to support critical life sciences functions, with access to the world's most comprehensive biomedical literature database.
Learn more about Embase

PharmaPendium

Enable better informed preclinical drug safety decisions with comprehensive, fully searchable FDA/EMA drug approval documents and comparative extracted drug safety data.
Learn more about PharmaPendium

QUOSA

Reduce time spent monitoring, organizing and annotating scientific and medical literature for triage and compliance reports such as PSURs and ICSRs.

Learn more about QUOSA

Pathway Studio

Enable better understanding of biological processes underlying disease progression and treatment response, with a solution that helps researchers interpret experimental data from scientific literature.
Learn more about Pathway Studio

ScienceDirect

Enable researchers to more effectively and efficiently search authoritative, fulltext scientific, technical and health content through the use of smart, intuitive functionality.
Learn more about ScienceDirect

Scopus

Help researchers discover trends, partners and experts with the world’s largest abstract & citation database of peer­reviewed literature, including tools to track, analyze and visualize research.
Learn more about Scopus